Among these potential therapeutic targets, the establishment of anti-IL-6 and TNF-α antibodies, as well as Janus kinase (JAK) inhibitor therapies for rheumatoid arthritis, have been the most successful. The gene discussed is IL6; the disease is rheumatoid arthritis.